ABSTRACT
Background: In the present chapter, we provide a comprehensive and up-to-date snapshot of nanoceutical materials that are either currently approved by the US FDA or in the FDA clinical trial process. Nanotherapeutics can garner and facilitate personalised medicine, targeted therapies with reduced side-effects, and artificial intelligence-aided patient monitoring. However, mega challengespersist, particularly regarding bio-distribution, metabolism, and excretion from body.
Methods: Medical and chemical databases like PUBMED and PUBCHEM were mined with the key words nano-medicine, nano-pharmacology, nano-adjuvants, and nano-drug medicine. Data mining resulted in hits of 7166, 16746, 25, and 113 manuscripts, respectively. Only SciE, Scopus, Embase, Index-medicus, Publon, Scimago, Medline, Google scholar, InCitesindexed, and peer-reviewed manuscripts were scrutinised and selected for comprehensive analysis.
Results: Nanomedicines of natural and synthetic origin show tremendous potentialin the field of regenerative medicine. A few successful products are translated into clinical trials and medical practice. Several research groups, including ours, have designed numerous metal nanoparticles (including silver, gold, zinc oxide, cerium oxide, terbium hydroxide, silica, titanium oxide, and copper) and demonstrated their regenerative properties using in vitro and invivo models with promising prospective. Strategies for modifying the material surface for effective bioregulation and cellular microenvironment are discussed in this chapter.
Conclusion: Nanomaterials, either alone or in conjugationwith drug, certainly fuel and foster the successful nanoceutical adjuvants in regenerative medicine therapies. Numerous steps must be climbed before commercial development, with focus on safety and long-term effects of nanoformulations.
